<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapy-related <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), often presenting as <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), has become the most serious long-term complication of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy and offers a unique opportunity to study chemical <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Seven cohorts of patients treated for six different types of <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> have been followed closely for leukemic complications, and 115 consecutive patients with t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, including 45 cases from the cohorts, have been investigated cytogenetically at our institutions during the past 16 years </plain></SENT>
<SENT sid="2" pm="."><plain>In patients primarily treated with <z:chebi fb="0" ids="22333">alkylating agents</z:chebi>, the risk of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> increased by approximately 1% per year from 2 to at least 8 years after start of treatment </plain></SENT>
<SENT sid="3" pm="."><plain>In most cases, the disease presented as t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with loss of a whole chromosome 5 or 7, or various parts of their long arms, and the <z:hpo ids='HP_0001909'>leukemias</z:hpo> were of FAB-subtypes M1, M2, or M4 </plain></SENT>
<SENT sid="4" pm="."><plain>In patients treated with drugs targeting at DNA-topoisomerase II, such as <z:chebi fb="0" ids="4911">etoposide</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, 4-epidoxorubicin, or <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi> combined with drugs reacting directly with DNA, such as <z:chebi fb="2" ids="27899">cisplatin</z:chebi> or <z:chebi fb="0" ids="22333">alkylating agents</z:chebi>, the risk of <z:hpo ids='HP_0001909'>leukemia</z:hpo> increased much more steeply from only one year after start of therapy </plain></SENT>
<SENT sid="5" pm="."><plain>These early <z:hpo ids='HP_0003674'>onset</z:hpo> cases often presented as overt <z:hpo ids='HP_0001909'>leukemia</z:hpo> of FAB-subtypes M4 or M5 with balanced translocations to chromosome bands 11q23 and 21q22, whereas later <z:hpo ids='HP_0003674'>onset</z:hpo> cases often shared characteristics with cases observed after therapy with <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> alone </plain></SENT>
<SENT sid="6" pm="."><plain>Both alkylation of DNA and poisoning of DNA-topoisomerase II may result in development of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with different clinical and cytogenetic characteristics </plain></SENT>
<SENT sid="7" pm="."><plain>There may be a synergistic leukemogenic effect between the two types of drug, and in patients with <z:mpath ids='MPATH_310'>germ cell tumors</z:mpath> treated with <z:chebi fb="0" ids="4911">etoposide</z:chebi>, <z:chebi fb="2" ids="27899">cisplatin</z:chebi> and <z:chebi fb="0" ids="3139">bleomycin</z:chebi>, reassessment suggested the risk of <z:hpo ids='HP_0001909'>leukemia</z:hpo> to increase exponentially with increasing doses of <z:chebi fb="2" ids="27899">cisplatin</z:chebi> and <z:chebi fb="0" ids="4911">etoposide</z:chebi> </plain></SENT>
</text></document>